APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection" (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.Bayer Co.; Boehringer Ingelheim; Bristol-Myers Squibb; Otsuka; Astellas; Gilead Sciences; Chugai; Mitsubishi Tanabe; Kyorin; Merck Sharp Dohme; Dainippon Sumitomo; Vertex Pharmaceuticals; Takeda; Zeria; Chugai Pharmaceutical; MSD; Tanabe-Mitsubishi; Daiichi-Sankyo; AbbVie; BMS; Roche; Abbott; Gilead; Kowa Souku; Sysmex; Chugai Pharmaceutical Co.; GlaxoSmithKline; Ajinomoto-Seiyaku; Given Imaging; Mitsubishi Tanabe Pharm; Taiho Yakuhin; Dainippon Sumitomo Pharm; Igaku-Seibutsugaku InstituteSCI(E)PubMedARTICLEmomata-tky@umin.ac.jp5681-7011